Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells Journal Article


Authors: Sobrero, A. F.; Aschele, C.; Guglielmi, A. P.; Mori, A. M.; Melioli, G. G.; Rosso, R.; Bertino, J. R.
Article Title: Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells
Abstract: Background: Our recent findings in vitro in the human colon adenocar-cinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule. Purpose: We tested the hypothesis that HCT-8 cells resistant to short-term 5-FU exposure retain sensitivity to continuous exposure and studied interactions between the two schedules. Methods: HCT-8 cell lines resistant to short-term (pulse) treatment with 5-FU or to continuous exposure were obtained by six exposures to different concentrations of 5-FU for 4 hours or 7 days. We used a monolayer clonogenic assay to determine 5-FU-induced cell kill in resistant HCT-8 cells and sensitive parent cells. Parent cells were exposed to different concentrations of 5-FU for 1, 4, or 24 hours (short term), for 7 days (continuous exposure), or in a combination of both types of schedules. In astudy of the mechanism of interaction between short-term and continuous exposure in parent cells, we performed flow cytometric DNA analysis to determine the percentage of cells in S phase and assays of thymidylate synthase inhibition in intact cells and of incorporation of [6-3H]5-FU nucleotides into nucleic acids. Results: Sensitive HCT-8 cells became fully resistant to 5-FU within five or six treatments, and low-dose continuous exposure almost immediately produced resistant clones. HCT-8 cells resistant to 5-FU given every 4 hours retained full sensitivity to continuous exposure, suggesting lack of cross-resistance between the two schedules, but cells resistant to continuous exposure were cross-resistant to short-term treatment Parent cells showed a statistically significant (synergistic) enhancement of the cytotoxic activity for 5-FU exposure for 1 hour (100,300, or 500 μM) followed by continuous exposure (0.5, 1, or 2 μM) or 4 hours (10, 30, or 60 μM) followed by continuous exposure (1 or 2 μM). Short-term plus continuous exposure produced a marked increase in percentage of S-phase cells, compared with the percentage for each schedule alone. The combination of 1-hour exposure and continuous exposure (1000 and 2 μM, respectively) produced a marked accumulation of cells in S phase at 24 hours (59%), which lasted up to 96 hours (53%). The combination of the two schedules produced only additive enhancement of thymidylate synthase inhibition as well as incorporation of [6-3H]5-FU nucleotides into nucleic acids of HCT-8 cells. Conclusions: Our findings provide a rationale for the use of bolus 5-FU and continuous infusion 5-FU in sequence. Implications: We are conducting a clinical trial of bolus methotrexate followed by continuous-infusion 5-FU plus leu-covorin. [J Natl Cancer Inst 85:1937-1944, 1993] © 1993 Oxford University Press.
Keywords: controlled study; human cell; fluorouracil; methotrexate; flow cytometry; adenocarcinoma; cell cycle; cell cycle s phase; drug administration schedule; colonic neoplasms; cytotoxicity; drug resistance; drug screening assays, antitumor; tumor cells, cultured; drug synergism; folinic acid; thymidylate synthase; colon adenocarcinoma; dna synthesis inhibition; cell killing; cross resistance; dose time effect relation; human; article; support, non-u.s. gov't
Journal Title: JNCI: Journal of the National Cancer Institute
Volume: 85
Issue: 23
ISSN: 0027-8874
Publisher: Oxford University Press  
Date Published: 1993-12-01
Start Page: 1937
End Page: 1944
Language: English
DOI: 10.1093/jnci/85.23.1937
PUBMED: 8230285
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 March 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joseph Bertino
    363 Bertino